抗癌药物S-1的当前进展
Current Development of Anti-Cancer Drug S-1.
作者信息
Chhetri Pratima, Giri Anil, Shakya Suraj, Shakya Sujana, Sapkota Binaya, Pramod K C
机构信息
Lecturer, Department of Pharmaceutical Sciences, Faculty of Health Science, Nobel College , Kathmandu, Nepal .
出版信息
J Clin Diagn Res. 2016 Nov;10(11):XE01-XE05. doi: 10.7860/JCDR/2016/19345.8776. Epub 2016 Nov 1.
Abstract
S-1 is a novel oral fluoropyrimidine derivative, widely used for treating gastric, pancreatic, lung, head, neck and breast carcinomas. It is designed to enhance the clinical utility of an oral fluoropyrimidine and is associated with low gastrointestinal toxicity. S-1 consists of three pharmacological agents (at a molar ratio of 1:0.4:1)-Tegafur (FT), a prodrug of 5-Fluorouracil (5-FU), 5-Chloro-2-4-Dihydroxypyridine (CDHP), which inhibits the activity of Dihydropyrimidine Dehydrogenase (DPD) and Oxonic Acid (Oxo), which reduces Gastrointestinal (GI) toxicity of 5-FU. The present article reviews the current development of clinical study of S-1.
摘要
S-1是一种新型口服氟嘧啶衍生物，广泛用于治疗胃癌、胰腺癌、肺癌、头颈癌和乳腺癌。它旨在提高口服氟嘧啶的临床效用，且胃肠道毒性较低。S-1由三种药理剂（摩尔比为1:0.4:1）组成——替加氟（FT），5-氟尿嘧啶（5-FU）的前体药物；5-氯-2,4-二羟基吡啶（CDHP），可抑制二氢嘧啶脱氢酶（DPD）的活性；奥昔嘌醇（Oxo），可降低5-FU的胃肠道（GI）毒性。本文综述了S-1临床研究的当前进展。
相似文献
1
Current Development of Anti-Cancer Drug S-1.抗癌药物S-1的当前进展
J Clin Diagn Res. 2016 Nov;10(11):XE01-XE05. doi: 10.7860/JCDR/2016/19345.8776. Epub 2016 Nov 1.
2
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.新型口服氟嘧啶前体药物S-1及其在胃肠道癌和其他实体瘤中的应用。
Anticancer Drugs. 2004 Feb;15(2):85-106. doi: 10.1097/00001813-200402000-00001.
3
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.替加氟、奥替拉西钾和5-氯-2,4-二羟基吡啶口服制剂S-1（摩尔比1:0.4:1）在实体瘤患者中的药代动力学。
Cancer Chemother Pharmacol. 2003 Jul;52(1):1-12. doi: 10.1007/s00280-003-0617-9. Epub 2003 May 9.
4
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.一种新型口服5-氟尿嘧啶衍生物（S-1）的研发，该衍生物通过两种生化调节剂增强5-氟尿嘧啶的肿瘤选择性细胞毒性。
Anticancer Drugs. 1996 Jul;7(5):548-57. doi: 10.1097/00001813-199607000-00010.
5
Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.在人肿瘤细胞中使用5-氯-2,4-二羟基吡啶（CDHP）抑制二氢嘧啶脱氢酶活性（DPD）来增强5-氟尿嘧啶（5-FU）的抗肿瘤活性。
Eur J Cancer. 2002 Jun;38(9):1271-7. doi: 10.1016/s0959-8049(02)00048-5.
6
[Pharmacokinetics of S-1].[S-1的药代动力学]
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:27-35.
7
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].[通过对5-氟尿嘧啶进行生化调控发明一种名为S-1的肿瘤选择性5-氟尿嘧啶衍生物]
Gan To Kagaku Ryoho. 1998 Feb;25(3):371-84.
8
Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.新型口服氟尿嘧啶抗肿瘤药物S-1对维持性血液透析慢性肾衰竭患者的安全性和有效性。
Oncology. 2004;66(5):358-64. doi: 10.1159/000079483.
9
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.新型口服氟尿嘧啶抗肿瘤药物S-1在动物模型及肾功能受损患者中的药代动力学研究
Cancer Chemother Pharmacol. 2002 Jul;50(1):25-32. doi: 10.1007/s00280-002-0457-z. Epub 2002 Apr 25.
10
[Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].[从5-氟尿嘧啶的发现到口服抗癌药物S-1的研发及其药物理念的时间线]
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:4-18.
引用本文的文献
1
Efficacy and Safety of a 3-Weekly TS-1 Adjuvant Regimen in Advanced Gastric Cancer: A Pilot Study.每三周一次替吉奥辅助治疗方案用于晚期胃癌的疗效与安全性：一项探索性研究
Cancer Med. 2025 Aug;14(15):e71079. doi: 10.1002/cam4.71079.
2
Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review.人类细胞色素P450与癌症相关的代谢活性及基因多态性：综述
Cells. 2024 Nov 26;13(23):1958. doi: 10.3390/cells13231958.
3
Efficacy and safety of anlotinib combined with S‑1 as a third‑ or later‑line treatment for advanced non‑small cell lung cancer in China: A systematic review and meta‑analysis.安罗替尼联合S-1作为中国晚期非小细胞肺癌三线及以上治疗的疗效和安全性：一项系统评价和荟萃分析
Oncol Lett. 2024 Oct 14;28(6):613. doi: 10.3892/ol.2024.14746. eCollection 2024 Dec.
4
Practical Consensus Guidelines for the Use of S-1 in GI Malignancies.S-1在胃肠道恶性肿瘤中应用的实用共识指南
South Asian J Cancer. 2024 Feb 5;13(1):77-82. doi: 10.1055/s-0043-1778685. eCollection 2024 Jan.
5
Synthesis of 5-fluorouracil-lactoside derivatives and experimental study on their anti-oral squamous cell carcinoma activity.5-氟尿嘧啶-乳糖苷衍生物的合成及其抗口腔鳞状细胞癌活性的实验研究
Hua Xi Kou Qiang Yi Xue Za Zhi. 2022 Jan 25;40(1):32-38. doi: 10.7518/hxkq.2022.01.005.
6
Less necessity of adjuvant S-1 treatment in non-monarchE-eligible patients.非 monarchE 适应证患者中辅助 S-1 治疗的必要性降低。
Cancer Med. 2023 Jun;12(12):13193-13203. doi: 10.1002/cam4.6006. Epub 2023 May 10.
7
A review on drug-induced dry eye disease.药物性干眼的研究进展。
Indian J Ophthalmol. 2023 Apr;71(4):1263-1269. doi: 10.4103/IJO.IJO_2782_22.
8
Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers.白细胞介素-6/信号转导与转录激活因子3轴在胃癌顺铂耐药中的作用
Biomedicines. 2023 Feb 24;11(3):694. doi: 10.3390/biomedicines11030694.
9
Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation.回复：合并间质性肺炎的肺癌的药物治疗：证据有限需要适当评估。
ERJ Open Res. 2022 Dec 12;8(4). doi: 10.1183/23120541.00469-2022. eCollection 2022 Oct.
10
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.1,3-双四氢呋喃-2-基-5-FU 的合成、表征及作为胰腺癌潜在治疗剂的抗癌活性评价。
BMC Cancer. 2022 Dec 22;22(1):1345. doi: 10.1186/s12885-022-10449-y.
本文引用的文献
1
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.晚期胃癌一线化疗失败后生存延长：日本临床肿瘤学组试验 JCOG9205 和 JCOG9912 的联合分析。
Gastric Cancer. 2014;17(3):522-8. doi: 10.1007/s10120-013-0309-z. Epub 2013 Oct 26.
2
Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies.替吉奥（S-1）与顺铂联合用于治疗成人晚期胃癌时已获批准：与其他基于氟嘧啶的疗法的比较综述。
Onco Targets Ther. 2011;4:193-201. doi: 10.2147/OTT.S19059. Epub 2011 Nov 15.
3
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients.中西方人群中 S-1 的药代动力学与药效学比较。
Cancer Sci. 2011 Feb;102(2):478-83. doi: 10.1111/j.1349-7006.2010.01793.x. Epub 2010 Dec 10.
4
A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study).术前化疗 S-1 联合顺铂加 D2/D3 胃切除术治疗临床浆膜阳性胃癌的 II 期研究（JACCRO GC-01 研究）。
Eur J Surg Oncol. 2010 Jun;36(6):546-51. doi: 10.1016/j.ejso.2010.04.011.
5
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis.多西他赛和 S-1 联合治疗晚期或复发性胃癌患者的一线治疗：回顾性分析。
World J Surg Oncol. 2010 May 19;8:40. doi: 10.1186/1477-7819-8-40.
6
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.氟尿嘧啶对比伊立替康联合顺铂与S-1治疗转移性胃癌：一项随机3期研究。
Lancet Oncol. 2009 Nov;10(11):1063-9. doi: 10.1016/S1470-2045(09)70259-1. Epub 2009 Oct 7.
7
Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.S-1与顺铂序贯给药用于转移性胃癌的I期研究。
Anticancer Res. 2009 May;29(5):1727-32.
8
Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706).S-1联合顺铂同步放化疗用于不可切除的局部晚期头颈部鳞状细胞癌患者的II期试验：日本临床肿瘤学组研究（JCOG0706）
Jpn J Clin Oncol. 2009 Jul;39(7):460-3. doi: 10.1093/jjco/hyp040. Epub 2009 May 8.
9
S-1: a promising new oral fluoropyrimidine derivative.S-1：一种有前景的新型口服氟嘧啶衍生物。
Expert Opin Investig Drugs. 2009 Mar;18(3):335-48. doi: 10.1517/13543780902729412.
10
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.口服抗癌药物S-1（替吉奥）的研发历史与概念：其临床应用价值及未来展望
Jpn J Clin Oncol. 2009 Jan;39(1):2-15. doi: 10.1093/jjco/hyn127. Epub 2008 Dec 3.
Zotero 插件